Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review.

摘要: Combined pegylated interferon (PEG-IFN)+ribavirin (RBV) therapy has been used as a primary treatment for chronic hepatitis C. However, IFN-induced autoimmune disease, including type 1 diabetes mellitus, highlighted one of the problems with this therapy. Here we report case patient who developed mellitus during combined PEG-IFN+RBV C but showed no exacerbation despite continued use IFN. A 63-year-old man and nonresponder to previous IFNa treatments, was admitted our hospital because excessive thirst, polydipsia, polyuria 24 weeks after start PEG-IFNa+RBV High levels blood glucose glycosylated hemoglobin low C-peptide immunoreactive insulin were observed. The serum antiglutamic acid decarboxylase antibody titer 27,700 U/mL. We diagnosed mellitus; however 48 weeks. Serum HCV remains negative five years treatment. Intensive started immediately diagnosis diabetes. Although initially required 22 U/day insulin, dosage could be gradually reduced completion remained well controlled. Prediction onset on basis baseline measurement pancreas-associated autoantibodies is difficult. Therefore, it would advisable consider possibility in all patients receiving IFN+RBV